share_log

Piper Sandler Maintains Overweight on Biogen, Raises Price Target to $360

Benzinga ·  Jun 1, 2023 09:18

Piper Sandler analyst Christopher Raymond maintains Biogen (NASDAQ:BIIB) with a Overweight and raises the price target from $346 to $360.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment